India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of
German pharma group Bayer has made another play in the digital medical imaging category, buying Blackford Analysis and its artificial intelligence-based platform for radiological assessment
Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-sta
mRNA specialist BioNTech has driven its partnership with UK artificial intelligence InstaDeep into top gear, agreeing to buy the company outright in a cash and equity deal that values it at
French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh